Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 11Plasma cell 3Lymphoid 2Genitourinary 2CNS 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Brain Neoplasms 592Glioblastoma 573Glioma 298Central Nervous System Neoplasms 208Gliosarcoma 177Neuroblastoma 175Astrocytoma 174Oligodendroglioma 112Carcinoma, Non-Small-Cell Lung 92Medulloblastoma 80Breast Neoplasms 74Ependymoma 61Sarcoma 60Meningioma 60Neoplasm Metastasis 57Recurrence 56Melanoma 56Neoplasms 51Lung Neoplasms 48Neurofibromatosis 1 43Meningeal Carcinomatosis 40Osteosarcoma 39Pheochromocytoma 38Rhabdomyosarcoma 37Wilms Tumor 36Paraganglioma 35Lymphoma, Non-Hodgkin 32Neuroectodermal Tumors, Primitive, Peripheral 29Lymphoma 27Sarcoma, Ewing 26

Interventions

Sirolimus 1Everolimus 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Peripheral Nervous System Diseases × CNS × Clear all
NCT03109301 2019-04-05

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
CNS

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

NCT01490476 2017-05-23

AFINF2

Assistance Publique - Hôpitaux de Paris

Phase 2 Completed
10 enrolled
CNS

Vestibulocochlear Nerve Diseases, Neuroma, Acoustic, Otorhinolaryngologic Diseases, Peripheral Nervous System Diseases, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡